We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline has been awarded a $274 million contract from the U.S. Department of Health and Human Services (HHS) to speed the development of new cell culture-based seasonal and pandemic influenza vaccines and to scale-up cell culture manufacturing capability at its Marietta, PA facility.
Friday, Nymox Pharmaceutical Corp. said it received certification in Europe with the CE Mark for its saliva-based version of its NicAlert product for testing for tobacco use.
Aerovance Inc., a biopharmaceutical company with a portfolio of clinical-stage drugs targeting severe respiratory and inflammatory diseases, today announced it has secured $60 million in Series C financing.
The U.S. government has committed approximately $149 million in support of the Zambian government's national program to fight HIV/AIDS -- a broad plan that will involve HIV-prevention education and increased access to antiretroviral (ARV) medications.
Health Canada has warned consumers not to use Sandoz's Prednisolone ophthalmic suspension eye drops because of the possibility that the bottles may mistakenly contain another product, Blue Collyrium -- a different type of eye drop that requires patients be monitored by a physician if the medication is used for longer than a 72-hour period.
Swiss biopharmaceuticals company Biopartners has received authorization to market its recombinant growth hormone Valtropin in the European Union (EU), the company reported.
Anti Aging Medical Group Corp, a specialty pharmaceutical company focused on developing, acquiring and commercializing innovative and scientifically proven products that offer both health maintenance and appearance enhancing benefits announces that due to its successful trip to China, Anti Aging Medical Group is considering opening a Hong Kong office in order to establish a stronger presence in the region.
Tripos, Inc., a leading provider of drug discovery chemistry and informatics products and services, today announced that it has completed the sale of 1.8 million shares of Convertible Preferred Stock at a price of $3.00 per share and issued 550,000 five-year common stock warrants exercisable at $3.50 per share to Midwood Capital, a Boston-based investment partnership.